Protein folding

Agilent Announces New Ion Mobility LC/Q-TOF and Enhanced Solutions for Biotherapeutics at ASMS 2021

Retrieved on: 
Monday, November 1, 2021
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Security, Other Science, Other Technology, Research, Software, Science, Chemistry, Peptide, Efficiency, Agilent Technologies, Research, University, LinkedIn, Title 21 CFR Part 11, Workflow, Â, Twitter, Organization, Protein folding, CIU, Beijing Spring, Pennsylvania Convention Center, Adoption, NYSE, Bravo, University of Michigan, Conference, Software, ASMS, Protein, Pressure, News, Solution, Therapy, Society, Automation, Medical device, Fine chemical

Agilent Technologies Inc. (NYSE: A) announced today the new Agilent 6560C Ion Mobility LC/Q-TOF , enhancements to the VWorks automation software suite, and new AssayMAP large capacity cartridges.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) announced today the new Agilent 6560C Ion Mobility LC/Q-TOF , enhancements to the VWorks automation software suite, and new AssayMAP large capacity cartridges.
  • These solutions will be on show at the American Society for Mass Spectrometry Conference (ASMS) which is being held October 31 - November 4, 2021, in Philadelphia, PA.
  • These products improve the analysis of proteins and peptides to speed up the development of new protein-based therapeutics in biopharma.
  • As the market for protein biotherapeutics expands, pressure increases to improve the efficiency and efficacy of the development process.

X-Chem Acquires Glamorous AI — Immediately Creating a Leader in DEL-Powered AI Solutions

Retrieved on: 
Thursday, October 28, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Biology, DEL, Chemistry, Technology, Protein folding, Organization, Patient, Drug discovery, Probability, Risk, CEO, Glamorous, Artificial intelligence, Solution, Acquisition, Chem, AI, Medical device, Pharmaceutical industry, X-Chem, Glamorous AI, X-CHEM, GLAMOROUS AI

X-Chem , the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI , a leader in artificial intelligence (AI) solutions for drug discovery.

Key Points: 
  • X-Chem , the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI , a leader in artificial intelligence (AI) solutions for drug discovery.
  • Coupling X-Chems high-quality DEL data with the innovative AI capabilities of Glamorous AI positions X-Chem as a leading service provider in machine learning-driven drug discovery.
  • What AlphaFold did for protein folding, X-Chem and Glamorous AI will do for drug discovery, said Matt Clark , Ph.D., CEO of X-Chem.
  • Glamorous AI brings cutting-edge solutions to the entire small molecule drug discovery process.

Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer

Retrieved on: 
Tuesday, October 19, 2021
Sucampo Pharmaceuticals, Tissue, Cooley LLP, Drug discovery, MJFF, CNS, Cartilage, Technology, General counsel, Protein folding, European Union, Cooley, Disease, HR, GBA, IP, The Michael J. Fox Foundation, Nasdaq, EVP, Therapy, Allosteric regulation, GLOBE, Brain, Patient, Glycogen storage disease, Star, SA, Forward-looking statement, Neurodegeneration, Business development, CAR, Company, Pharmaceutical industry, Fine chemical

I am delighted to welcome Matthias to Gains growing team as we methodically scale our platform and build our internal clinical trial capabilities and operations, said Eric Richman, Chief Executive Officer of Gain.

Key Points: 
  • I am delighted to welcome Matthias to Gains growing team as we methodically scale our platform and build our internal clinical trial capabilities and operations, said Eric Richman, Chief Executive Officer of Gain.
  • Matthias Alder joins Gain with more than 25 years of transactional, operational, and business development experience in the pharmaceutical and biotechnology industries.
  • Most recently, Mr. Alder was Chief Business Officer at Autolus Therapeutics, a biotechnology company focused on developing CAR T-cell therapies for hematological and solid tumors, where he led the corporate development, legal, IP and HR functions.
  • In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431

Retrieved on: 
Wednesday, September 29, 2021
HEPA, Cell death, Cmax, Pharmacokinetics, Failure, PK, Liver disease, Risk, DDI, Security (finance), Inflammation, Ill, Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, FDA, Patient, Lipidomics, Artificial intelligence, Cyclophilin, Ketoconazole, Consequential damages, Metabolomics, Metabolism, Hypertension, Polypharmacy, NASH, Diabetes, Industry, Genomics, Company, Proteomics, Family, Fatty liver disease, Disease, Drug, HDV, Liver, COVID-19, Cirrhosis, Drug development, Safety, Response, HCV, Doctor of Philosophy, HBV, Protein folding, Government, Precision medicine, Midazolam, Enzyme, GLOBE, Pharmaceutical industry

The study also examined if single or multiple once daily oral doses of CRV431 effected the PK of midazolam (2 mg IV) and its metabolite, 1-hydroxymethyl midazolam.

Key Points: 
  • The study also examined if single or multiple once daily oral doses of CRV431 effected the PK of midazolam (2 mg IV) and its metabolite, 1-hydroxymethyl midazolam.
  • Additionally, the safety and tolerability of CRV431 when administered concomitantly with either ketoconazole or midazolam was assessed.
  • The minimal interaction with midazolam demonstrates that CRV431 can be safely administered with other drugs metabolized through this pathway.
  • Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement.

Attralus Appoints Jake Bauer to Board of Directors

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Protein folding, Amyloidosis, Bauer, Transthyretin

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that Jake Bauer joined the companys Board of Directors as an independent director.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that Jake Bauer joined the companys Board of Directors as an independent director.
  • We are delighted to welcome Mr. Bauer to our Board of Directors.
  • Mr. Bauer currently serves as a member of the Board of Directors for Enliven Therapeutics, Phoenix Tissue Repair, Inc. and Arya Sciences Acquisition Corp V.
    It is a privilege to join Attralus Board at this exciting time in the companys evolution, said Mr. Bauer.
  • Attralus was founded by scientific experts in the field of amyloidosis and is headquartered in South San Francisco, California.

Major shareholder announcement

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Biology, Lipid storage disorders, Rare diseases, Protein folding, Neurological disorders, Neurodegenerative disorders, Heat shock response, Niemann–Pick disease, type C, Heat shock protein, Niemann–Pick disease, Arimoclomol

Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases.

Key Points: 
  • Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases.
  • The company is harnessing amplification of heat shock proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction.
  • Arimoclomol, the companys lead candidate, is in clinical development for rare diseases including Niemann-Pick disease type C (NPC) and Gaucher disease.
  • Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland.

Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis

Retrieved on: 
Thursday, June 24, 2021
Health, FDA, Genetics, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Amyloidosis, Branches of biology, Organ systems, Nervous system, Neurological disorders, Protein folding, Familial amyloid polyneuropathy, Orphan drug, Peripheral neuropathy, Polyneuropathy, Wild-type transthyretin amyloid, PTC Therapeutics, Vutrisiran, the HELIOS-A Phase 3 Study, hATTR Amyloidosis, RNAi, Alnylam Pharmaceuticals, VUTRISIRAN, THE HELIOS-A PHASE 3 STUDY, HATTR AMYLOIDOSIS, RNAI, ALNYLAM PHARMACEUTICALS

If approved, once-quarterly, subcutaneously administered vutrisiran may represent a new treatment option that potentially reverses polyneuropathy manifestations of disease.

Key Points: 
  • If approved, once-quarterly, subcutaneously administered vutrisiran may represent a new treatment option that potentially reverses polyneuropathy manifestations of disease.
  • Vutrisiran has been granted Orphan Drug Designation in the U.S. and the European Union (EU) for the treatment of ATTR amyloidosis.
  • Vutrisiran has also been granted a Fast-Track designation in the U.S. for the treatment of the polyneuropathy of hATTR amyloidosis in adults.
  • Vutrisiran is an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of ATTR amyloidosis, which encompasses both hereditary (hATTR) and wild-type (wtATTR) amyloidosis.

Major shareholder announcement

Retrieved on: 
Wednesday, June 23, 2021
Branches of biology, Biology, Lipid storage disorders, Rare diseases, Protein folding, Neurological disorders, Neurodegenerative disorders, Heat shock response, Niemann–Pick disease, type C, Heat shock protein, Niemann–Pick disease, Arimoclomol

Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases.

Key Points: 
  • Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases.
  • The company is harnessing amplification of heat shock proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction.
  • Arimoclomol, the companys lead candidate, is in clinical development for rare diseases including Niemann-Pick disease type C (NPC) and Gaucher disease.
  • Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland.

DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma

Retrieved on: 
Tuesday, June 22, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Drugs, Orphan drugs, Amyloidosis, Daratumumab/hyaluronidase, Protein folding, Daratumumab, AL amyloidosis, Cyclophosphamide, Bortezomib

This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe.

Key Points: 
  • This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe.
  • The study includes 388 patients with newly diagnosed AL amyloidosis with measurable haematologic disease and one or more organs affected.
  • This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding daratumumab subcutaneous formulation for the treatment of patients with light chain amyloidosis.
  • Subcutaneous Daratumumab + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients With Newly Diagnosed Light Chain (AL) Amyloidosis: Updated Results From the Phase 3 ANDROMEDA Study.

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Amyloidosis, Branches of biology, Proteins, Anatomy, Neurological disorders, Protein folding, Histopathology, Structural proteins, Familial amyloid polyneuropathy, Transthyretin, NTLA, Amyloid

The presentation will include interim data from the ongoing dose-escalation portion of Intellias Phase 1 trial evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN).

Key Points: 
  • The presentation will include interim data from the ongoing dose-escalation portion of Intellias Phase 1 trial evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN).
  • Following safety assessment and dose optimization, Intellia intends to further evaluate NTLA-2001 in a broader population of people with ATTR amyloidosis, including those with cardiomyopathy.
  • Intellia will host a live webcast on Monday, June 28, 2021 at 8:00 a.m. E.T.
  • Intellias global Phase 1 trial is an open-label, multi-center, two-part study of NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN).